PulmCCM

Share this post

Pirfenidone's long trudge to FDA approval: InterMune launches new trial (ASCEND-3)

www.pulmccm.org

Pirfenidone's long trudge to FDA approval: InterMune launches new trial (ASCEND-3)

Aug 13, 2011
Share
Share this post

Pirfenidone's long trudge to FDA approval: InterMune launches new trial (ASCEND-3)

www.pulmccm.org

Unimpressed by the unimpressive results of the CAPACITY trials testing pirfenidone for idiopathic pulmonary fibrosis, the FDA bucked its advisory panel (which had recommended approval) and insisted on another randomized trial in order to reconsider the drug.

In July 2011 InterMune started enrollment for ASCEND, which plans to provide results on pirfenidone vs. placebo in ~500 patients with IPF in mid-2013. Pirfenidone would not likely be approved until early 2014, according to news reports and press releases.

Share
Share this post

Pirfenidone's long trudge to FDA approval: InterMune launches new trial (ASCEND-3)

www.pulmccm.org
Previous
Next
Comments
Top
New
Community

No posts

Ready for more?

© 2023 PulmCCM
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing